| abstract |
The disclosure features a method of treating cancer, angiogenesis-related disorders, and lymphangiogenesis-related disorders using plasmin inhibitors. An exemplary method involves administering to a subject a plasmin inhibitor (eg, a protein comprising a Kunitz domain that inhibits plasmin). In one embodiment, the plasmin inhibitor is one that does not substantially achieve hemostasis. In one embodiment, the plasmin inhibitor does not substantially inhibit other proteases. In one embodiment, the Kunitz domain can include at least two polymer moieties (eg, polymer moieties attached to each primary amine). |